Haemolytic anaemia triggered by antitumoural "biological agents" and immunotherapies with monoclonal antibodies: Short review of the literature

Memo - Magazine of European Medical Oncology

Volumn 3, Issue 1, 2010, Pages 19-22

  Sun, W L ^a,b   Walder, A ^c   Fiegl, Michael ^d  

^a Academic Natters Hospital   (Austria)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Biologicals; Haemolytic anaemia; Lenalidomide; Therapeutic antibodies

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AUTOANTIBODY; BEVACIZUMAB; BORTEZOMIB; FLUDARABINE; IMATINIB; IMMUNOGLOBULIN; LENALIDOMIDE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; PROBENECID; RITUXIMAB; SORAFENIB; STEROID; SUNITINIB; THYMOCYTE ANTIBODY;

5Q- SYNDROME; ACUTE LEUKEMIA; ALLOIMMUNITY; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BLOOD TRANSFUSION; CANCER IMMUNOTHERAPY; CHROMOSOME 20Q; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COOMBS TEST; CRYOGLOBULINEMIA; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; GASTROINTESTINAL STROMAL TUMOR; GRAFT REJECTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNE DYSREGULATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LUNG ALVEOLUS CELL CARCINOMA; METASTASIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RHABDOMYOLYSIS; SHORT SURVEY; SPLENECTOMY; TREATMENT DURATION; UREMIA;

EID: 77955673022     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-010-0174-y     Document Type: Short Survey

References (28)

1. List A, Kurtin S, Roe DJ, et al. Effi cacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 352: 549-557, 2005.
2. Darabi K, Kantamnei S, Wiernik PH. Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol, 24: e59, 2006.
3. Sun WL, Koeck L, Walder A, et al. Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis. Anna Hematol, Epub ahead of print
4. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent Bortezomib for the treatment of patients with fl udarabine-refractory B-cell chronic lymphocytic leukemia. Cancer, 107: 916-924, 2006.
5. Novaretti MCZ, Fonseca GHH, Conchon M, et al. First case of immune- mediated haemolytic anaemia associated to imatinib mesylate. Eur J Haematol, 71: 455-458, 2003.
6. De Arriba JJ, Nerin C, Garcia E, et al. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol, 14: 962, 2003.
7. Jain R, Mathew P, Wood CG, et al. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer, 6: 122-123, 2008.
8. Berchem G, Dewilde S, Mahassen P. A case of acute haemolysis with 2 diff erent multi target thyrosine kinase inhibitors in a patient with renal cancer. Bull Soc Sci Med Grand Duche Luxemb, 1: 7-9, 2009.
9. Ruch J, McMahon B, Ramsey G, et al. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol, 84: 120-122, 2009.
10. Ramamoorthy SK, Marangolo M, Durrant E, et al. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. Leuk Lymphoma, 47: 747-750, 2006.
11. Jourdan E, Topart D, Richard B, et al. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma, 44: 889-890, 2003.
12. Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica, 92: 1029-1036, 2007.
13. Kako S, Kanda Y, Oshima K, et al. Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol, 83: 247-249, 2008.
14. Fiegl M, Falkner A, Hopfi nger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer, 107: 2408-2416, 2006.
15. Wierda WG, Kipps TJ, Keating MJ, et al. Self-administered, subcutaneous alemtuzumab to eliminate residual disease in patients with CLL. Blood, 108(abstract 2839), 2006.
16. Frangie C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol, 8: 177-178, 2007.
17. Eremina V, Jeff erson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med, 358: 1129-1136, 2008.
18. Galesic K, Bozic B, Racic I, et al. Th rombotic microangiopathy associated with s-interferon therapy for chronic myeloid leukemia. Nephrology, 11: 49-52, 2006.
19. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol, 13: 2401-2407, 1995.
20. Takase K, Nakano T, Hamada M, Shiraki K, Oohashi Y, Kihira T, Tameda Y. Hemolytic anemia provoked by recombinant alpha-interferon. J Gastroenterol, 30: 795-797, 1995.
21. Cauli C, Serra G, Chessa L, et al. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. Haematologica, 91: e76-e77, 2006.
22. Lambotte O, Gelu-Simeon M, Maigne G, et al. Pegylated interferon alpha-2a-associated life-threatening Evens' syndrome in a patient with chronic hepatitis C. J Infection, 51: e113-e115, 2005.
23. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fl udarabine therapy for chronic lymphocytic leukemia. J Clin Oncol, 16: 1885-1889, 1998.
24. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fl udarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol, 136: 800-805, 2007.
25. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol, 72: 79-88, 2004. (Pubitemid 38161156)
26. Giagounidis AA, Haase S, Germing U, et al. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol, 113: 146-149, 2005.
27. Novaretti MC, Sopelete CR, Velloso ER, et al. Immunohematological fi ndings in myelodysplastic syndrome. Acta Haematol, 105: 1-6, 2001.
28. Wolf D. IMiDs induce pleiotropic anti-cancer eff ects. memo, Suppl 1: 10-12, 2009.